ReviewClinical microbiology reviews2017
Bacterial and Fungal Endophthalmitis.
Review in Clinical microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 257 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
257 citing papers in PubMed, 493 citations in OpenAlex.
- Understanding the science of fungal endophthalmitis - AIOS 2021 Sengamedu Srinivas Badrinath Endowment Lecture.Indian journal of ophthalmology · 2022Trial
- Visual Acuity Influences Visual Outcome in Endophthalmitis: A 10-Year Retrospective Observational Cohort Analysis.Ophthalmology and therapy · 2026Article
- Beyond the Barrier: Overcoming Ocular Antimicrobial Resistance Through AI and Novel Therapeutics.International journal of molecular sciences · 2026Review
- A Case Report of Endogenous Endophthalmitis Associated With a Pyogenic Liver Abscess Caused by Hypervirulent Klebsiella pneumoniae.Immunity, inflammation and disease · 2026Article
- Metagenomic next-generation sequencing for comprehensive pathogen detection in intraocular infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Pathogen Spectrum and Antimicrobial Susceptibility Profiles in Culture-Proven Endophthalmitis at a Tertiary Referral Center in China: A Three-Decade Retrospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- Microbiological etiology of endogenous and exogenous postprocedural endophthalmitis: a 5-year German federal state study.Infection · 2026Article
- Endophthalmitis Requiring Enucleation in a Sedated Critically Ill Patient: A Case Report.Cureus · 2026Article
- Intravitreal rezafungin and anidulafungin in a rabbit model of Aspergillus fumigatus endophthalmitis.Scientific reports · 2026Article
- Review
- Development and preclinical evaluation of quiniodochlor-loaded nanostructured lipid carrier-chitosan gel for topical antifungal therapy.Discover nano · 2026Article
- Review
- Beyond Antibiotics: The Expanding Role of Non-Antibiotic Therapies in Veterinary Ophthalmology.Veterinary sciences · 2026Review
- Immunotherapy in Ocular Fungal Infections: Advances and Emerging Strategies.Current microbiology · 2026Review
- ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy.Materials today. Bio · 2026Article
- Optimization of corneal preservation media with novel antifungal agents.Archives of microbiology · 2026Article
- Ocular complications after liver transplantation: A comprehensive review of infectious and non-infectious etiologies.World journal of transplantation · 2026Review
- Chitosan-Coated Silver-Vancomycin Nanoparticles for Treatment of Bacterial Endophthalmitis.Investigative ophthalmology & visual science · 2026Article
197 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endophthalmitis is a severe eye infection that may result in permanent loss of useful vision in the affected eye. Most cases are exogenous and occur as a complication of cataract surgery, an intravitreal injection, or penetrating ocular trauma. Endogenous endophthalmitis results from hematogenous seeding of the eye by bacteria or fungi, but bacteremia or fungemia may be transient and patients may present without symptoms of systemic infection. Nearly all endophthalmitis patients present with decreased vision, and some also have eye pain. Eye examination usually reveals a hypopyon and intraocular inflammation. Diagnosis is clinical, supported by cultures of the vitreous and/or aqueous or by blood cultures in some endogenous cases. Molecular diagnostic techniques have been used in research laboratories for pathogen identification in endophthalmitis and offer the possibility of rapid diagnosis, including in culture-negative cases. Intravitreal injection of antibiotics is the most important component of treatment; some cases also benefit from surgical debridement of the vitreous by a vitrectomy. The visual outcome depends partly on the pathogen: coagulase-negative staphylococcal endophthalmitis has a better prognosis than does streptococcal endophthalmitis, for example. Endophthalmitis is a medical emergency, and prompt diagnosis and treatment are essential for saving vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.